BPC-157, gentamicin and the rat kidney

A paper published in June 2026 in the Journal of Physiology and Pharmacology reports that BPC-157 counteracted gentamicin-induced kidney damage in rats, and that the effect ran through the nitric oxide system^[1]. Read that sentence again and notice the word rats. This is a rodent result from one laboratory. BPC-157 has no approved human indication anywhere we cover, and no controlled human trial has tested it for kidney protection of any kind. What follows is a walk through what the study did, what it found, and the several reasons the finding does not carry across to a person.

What the study did

The researchers gave male Wistar rats gentamicin at 100 mg/kg intraperitoneally every day for eight days, which is the standard way to produce reliable kidney injury in a rodent^[1]. BPC-157 was given at two widely separated amounts, 10 µg/kg and 10 ng/kg, either in the drinking water or by daily intraperitoneal injection^[1]. Those are animal exposures reported by the investigators, not a human protocol, and nothing here converts into one.

The part the title advertises is the triple nitric oxide agent design. Alongside the peptide, the team ran three pharmacological probes of the same system: L-NAME at 5 mg/kg daily, which blocks the enzymes that make nitric oxide; L-arginine at 100 mg/kg daily, which supplies the raw material those enzymes use; and both agents together^[1]. The logic is that if a drug works through nitric oxide, blocking or boosting that system should bend the drug's effect in a predictable direction. It is a reasonable way to interrogate a mechanism in an animal, and it is the house method of the group that has run most BPC-157 research for three decades.

What it reported

On the peptide arms, the abstract describes a clinical picture close to normal: serum urea and creatinine (two waste products the kidney clears, both of which climb when it stops clearing them) back near baseline, urine output maintained, the increase in kidney mass avoided, and the tubular epithelium preserved^[1]. Kidney malondialdehyde, a marker of oxidative damage to cell membranes, fell, while nitric oxide and superoxide dismutase levels were restored^[1].

The nitric oxide probes behaved oddly, and that is the more interesting half. L-NAME on its own gave partial protection, with a "decrease of the increased urea and creatinine serum values, delayed polyuria, avoided oliguria, less tubular necrosis"^[1]. L-arginine on its own made things worse, producing "a further increase of urea and creatinine serum values, polyuria, oliguria"^[1]. The two combined produced "even stronger lesions, and more pronounced oliguria"^[1]. Against all of that, the authors write that BPC-157 regimens "overwhelmed these NO-agents' effects"^[1]. A compound that reverses the direction of both a nitric oxide blocker and a nitric oxide precursor is doing something more complicated than sitting on one node of that pathway, and the paper does not pin down what.

Why this model is not a hospital ward

Gentamicin nephrotoxicity in people is a genuine clinical problem. The antibiotic accumulates in the proximal tubular cells of the kidney and damages them, and a review cited by the StatPearls chapter on gentamicin found mild proteinuria and reduced glomerular filtration in 14% of users^[2]. It is also frequently reversible, because those tubular cells retain the capacity to regenerate, and patients on the drug have renal function checked twice weekly using serum creatinine and blood urea nitrogen^[2].

Set that next to the rat protocol. Eight consecutive days at 100 mg/kg is an injury model engineered to produce a large, readable signal in a small animal, not a simulation of how the antibiotic is dosed and monitored in a clinic. A compound that blunts a deliberately severe insult in a rat has told you something about the rat. Whether it does anything at human exposures, against human-scale injury, in kidneys with human comorbidities and human co-medications, is untested.

The general track record here is not encouraging. A BMJ systematic review compared animal and human results across six interventions that had both, and found discordance in several of them, concluding that the mismatch "may be due to bias or to the failure of animal models to mimic clinical disease adequately"^[3]. Organ protection is one of the categories where that gap tends to show up.

The single-laboratory problem

Every affiliation on this paper traces back to Croatia, mostly to the Department of Pharmacology at the School of Medicine, University of Zagreb, with the pathology work done in the same institution^[1]. That is the pattern for the field, not an exception. STAT reported in February 2026 that "almost all the existing data on BPC-157 comes from a single group of researchers in Croatia", led by Predrag Sikiric, who has published more than 150 papers on the compound^[4].

Concentration of that kind is not misconduct, and the work is peer-reviewed. It does mean the result has not been reproduced by a laboratory with no stake in the answer, which is the check that normally turns an interesting animal finding into something a regulator will look at. Until an independent group runs the same model and gets the same numbers, the BPC-157 evidence base on organ protection rests on one team's hands.

Where this leaves a reader

Nowhere near a decision. The US Department of Defense's Operation Supplement Safety programme states plainly that "BPC-157 is not a dietary ingredient. It is an unapproved drug and cannot be legally prescribed or sold over the counter", and that there is "little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans"^[5]. It holds no marketing authorisation in Denmark, Sweden, Norway, Germany, the Netherlands, the UK or the US.

One more thing worth saying out loud, because the framing of this paper invites the opposite reading. Drug-induced kidney injury is managed with monitoring, dose adjustment and drug withdrawal under supervision. It is not a problem to take on privately with an unregulated vial, and anyone worried about a nephrotoxic medication should be raising it with the prescriber rather than reading rodent papers. The regulation section of the BPC-157 page covers the legal picture country by country, and the cluster articles on how BPC-157 is thought to work and what the dosing literature actually contains cover the mechanism and the numbers in more depth. Neither of them, and not this paper either, changes the unapproved status of the compound.